In patients with cancer, fibrinolysis is counteracted by plasminogen-activator inhibitors (PAI) 1 and 2 that are particularly activated by cancer cells, resulting in enhanced chances of developing VTE [22]. This evidence concerns the gene SERPINB2 and cancer.